Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass

Shvetank Agarwal, Beth Ullom, Yasser Al-Baghdadi, Michael Okumura

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and the various elements during CPB that may alter its plasma levels. We report a case where the challenges in dosing argatroban led to failure to provide adequate anticoagulation during CPB, as evidenced by clot formation in the oxygenator, and extensive bleeding in the postoperative period.

Original languageEnglish (US)
Pages (from-to)106-110
Number of pages5
JournalJournal of Anaesthesiology Clinical Pharmacology
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Heparin
Oxygenators
Postoperative Period
Thrombocytopenia
Pharmacokinetics
Hemorrhage
argatroban

Keywords

  • Anti-coagulation
  • argatroban
  • cardio-pulmonary bypass
  • heparin alternative
  • heparin induced thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. / Agarwal, Shvetank; Ullom, Beth; Al-Baghdadi, Yasser; Okumura, Michael.

In: Journal of Anaesthesiology Clinical Pharmacology, Vol. 28, No. 1, 01.01.2012, p. 106-110.

Research output: Contribution to journalArticle

Agarwal, Shvetank ; Ullom, Beth ; Al-Baghdadi, Yasser ; Okumura, Michael. / Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. In: Journal of Anaesthesiology Clinical Pharmacology. 2012 ; Vol. 28, No. 1. pp. 106-110.
@article{f50eda3ddf38410bafe847f438d4ff59,
title = "Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass",
abstract = "Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and the various elements during CPB that may alter its plasma levels. We report a case where the challenges in dosing argatroban led to failure to provide adequate anticoagulation during CPB, as evidenced by clot formation in the oxygenator, and extensive bleeding in the postoperative period.",
keywords = "Anti-coagulation, argatroban, cardio-pulmonary bypass, heparin alternative, heparin induced thrombocytopenia",
author = "Shvetank Agarwal and Beth Ullom and Yasser Al-Baghdadi and Michael Okumura",
year = "2012",
month = "1",
day = "1",
doi = "10.4103/0970-9185.92458",
language = "English (US)",
volume = "28",
pages = "106--110",
journal = "Journal of Anaesthesiology Clinical Pharmacology",
issn = "0970-9185",
publisher = "Journal of Anaesthesiology Clinical Pharmacology",
number = "1",

}

TY - JOUR

T1 - Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass

AU - Agarwal, Shvetank

AU - Ullom, Beth

AU - Al-Baghdadi, Yasser

AU - Okumura, Michael

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and the various elements during CPB that may alter its plasma levels. We report a case where the challenges in dosing argatroban led to failure to provide adequate anticoagulation during CPB, as evidenced by clot formation in the oxygenator, and extensive bleeding in the postoperative period.

AB - Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and the various elements during CPB that may alter its plasma levels. We report a case where the challenges in dosing argatroban led to failure to provide adequate anticoagulation during CPB, as evidenced by clot formation in the oxygenator, and extensive bleeding in the postoperative period.

KW - Anti-coagulation

KW - argatroban

KW - cardio-pulmonary bypass

KW - heparin alternative

KW - heparin induced thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84857548205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857548205&partnerID=8YFLogxK

U2 - 10.4103/0970-9185.92458

DO - 10.4103/0970-9185.92458

M3 - Article

VL - 28

SP - 106

EP - 110

JO - Journal of Anaesthesiology Clinical Pharmacology

JF - Journal of Anaesthesiology Clinical Pharmacology

SN - 0970-9185

IS - 1

ER -